---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-26-004609"
form_type: "8-K"
ticker: "SLXN"
cik: "0002022416"
company_name: "Silexion Therapeutics Corp"
filed_at: "2026-09-25T20:15:34+00:00"
generated_at: "2026-10-12T13:22:56.453173+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.72
calibrated_materiality_score: 0.72
confidence: "high"
source: SEC EDGAR
---

# Silexion gets Nasdaq bid-price notice after 30 days below $1.00; hearings panel to weigh listing

## Summary
- Nasdaq Listing Qualifications staff letter dated September 25, 2026 says SLXN ordinary shares closed below the $1.00 minimum bid for 30 consecutive business days, breaching Listing Rule 5550(a)(2).
- Nasdaq's hearings panel will consider the bid price deficiency in deciding whether Silexion may remain listed on the Nasdaq Capital Market.
- Nasdaq says the letter has no immediate effect: ordinary shares keep trading as SLXN and listed warrants keep trading as SLXNW.
- Warrants to buy ordinary shares carry an exercise price of $15,525.00 per share; ordinary shares have $0.135 par value.
- Company says it cannot assure ongoing compliance with the bid price rule or other Nasdaq listing requirements.

## SEC filing metadata
- accession: 0001178913-26-004609
- form_type: 8-K
- ticker: SLXN
- cik: 0002022416
- company_name: Silexion Therapeutics Corp
- filed_at: 2026-09-25T20:15:34+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.72
- calibrated_materiality_score: 0.72
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2022416/000117891326004609/0001178913-26-004609-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2022416/000117891326004609/zk2636161.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-26-004609
- JSON: https://secwatch.observer/filing/0001178913-26-004609.json
- Plain text: https://secwatch.observer/filing/0001178913-26-004609.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.